

## Anti-Siglec-3/CD33 Antibody (LintuzumAb)

### Introduction

Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces TNF $\alpha$ -induced proinflammatory cytokine and chemokine production by AML cells. Lintuzumab exerts tumor cell killing effects on MDR<sup>-</sup> and MDR<sup>+</sup> AML cell lines and primary AML patient samples through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities. Lintuzumab improves the survival rate of tumor-bearing mice and reduces tumor burden.

### Product parameters

Alternative Names	SGN-33, HuM195, Actimab-A
Target Accession	O14793
Target	GDF8 / Myostatin
CAS number	166089-32-3
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 $\mu$ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80 $^{\circ}$ C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



### **APEx BIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

